Advertisement
Providing credible, world-class and free healthcare information to boththe general public and medical professionals in China, JK1 is the firsthealthcare web portal in China to source contents from world renownedinstitutions such as the National Cancer Institute, Harvard University,Stanford University, University of Vanderbilt and other well knowninstitutions in the U.S.
Advertisement
JK1 will be divided into two sections -- the public and the professionalsections. By lending the medical community easy, online access to this wealthof cutting edge information, in particular in oncology, JK1 is a uniquemilestone initiative which has the potential to change the cancer and publichealth landscape in China, hence benefiting both professionals and the publicat large.
The public section of the web portal will be officially launched inBeijing, China on 14 September 2007. For the next 2 years from the date oflaunch, NCN will supply JK1 with Chinese news articles on the medical andhealthcare areas.
"We are truly honored and excited to be entering into this strategicalliance with Xinhua News Agency through NCN in JK1. We are confident thatJK1 will be able to serve with much impact in helping to notch up thehealthcare standards in China. JK1 will also contribute towards facilitatingprofessional exchanges between China and the rest of the world, which is atthe heart of Bridgetech's vision," said Michael Chermak, Chairman and CEO ofBridgetech Holdings International, Inc.
About N.C.N. Limited and Xinhua News Agency
NCN is the sole agent of Xinhua News Agency's news products in the Asia-Pacific region, supplying Chinese and English news as well as Chinese economicinformation. NCN's operations also include publication, distribution,advertisement, business consultation, translation and newspaper clipping.Xinhua News Agency is the state and worldwide news agency in China.
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in Chinaand the U.S. to capitalize on the demand for Western healthcare in GreaterChina. The company is bringing emerging drugs, devices and diagnostics toGreater China, with an initial focus on oncology. For additional information,please visit Bridgetech at http://www.bthi.com.
Forward-Looking Statements
Statements contained in this press release that are not statements ofhistorical fact are "forward-looking statements" as that term is defined underfederal securities laws, including, without limitation, all statementsconcerning expectations, beliefs, goals, intention or strategies for thefuture of Bridgetech. Forward-looking statements may be identified by wordssuch as "goals," "plans," "believes," "will," "expects" and other words ofsimilar meaning used in conjunction with, among other things, discussions offuture operations, financial performance, product development and newventures. Many factors could cause actual events or results to differmaterially from those expressed in any forward-looking statement. Investorsare cautioned not to place any undue reliance on any forward-lookingstatements.Contacts: Media Relations US: Vince Heald, Beck Ellman Heald - (858) 453-9600 [email protected] Media Relations Hong Kong: Andrew Cheung, A-World Consulting - (852) 2114 4976 / 9205 2610 [email protected] Investor Relations: Redwood Consultants, LLC - 415-884-0348
SOURCE Bridgetech Holdings
